Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06FQS
|
|||
| Former ID |
DNCL003135
|
|||
| Drug Name |
TGOF02N
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Phase 2 | [1] | |
| Company |
Fabre-Kramer Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2 receptor (5HT2R) | Target Info | Modulator | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals. | |||
| REF 2 | Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.